CD8A and non-small cell lung carcinoma: It was reported that PD-1high CD8+ T cells predicted response to PD-1 blockade and correlated with increased overall survival and 80% of patients with clinical benefit exhibited PD-1+ CD8+ T-cell responses to PD-1 targeted immunotherapy in non-small cell lung cancer (31, 32).